● Recruiting

Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

Condition: Moderate to Severe Acute Postoperative Pain · Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

PhasePhase 2

Planned participants72

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Renhai Yang · 021-64311017 · clinical_trial@hllife.com.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07147049